Market cap
$3 Mln
Recently Viewed
Clear All$0.07
$-0.09
(-56.25%)
As on 08-Aug-2025 09:30EDT
Market cap
$3 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.6
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-2.3 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-0.2
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
17,212,200
CFO
$-396.87 Mln
EBITDA
$-459.21 Mln
Net Profit
$-475.85 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Unity Biotechnology (UBX)
| -92.8 | -76.7 | -92.2 | -95.0 | -79.9 | -76.8 | -- |
|
BSE Sensex*
| -9.2 | 6.9 | -6.5 | -4.2 | 8.0 | 9.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Unity Biotechnology (UBX)
| -49.1 | -29.6 | -81.2 | -72.1 | -27.3 | -55.7 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Unity Biotechnology (UBX)
|
0.1 | 3.4 | 0.0 | -27.5 | -- | -- | -- | 2.6 |
| 8.1 | 375.7 | 0.5 | -92.2 | -21,199.8 | -163.3 | -- | 9.1 |
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Its lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of... age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. The company also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, an a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California. Read more
CEO & Director
Dr. Anirvan Ghosh Ph.D.
CEO & Director
Dr. Anirvan Ghosh Ph.D.
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Unity Biotechnology Inc (UBX) is $0.07 (NASDAQ) as of 08-Aug-2025 09:30 EDT. Unity Biotechnology Inc (UBX) has given a return of -79.92% in the last 3 years.
Since, TTM earnings of Unity Biotechnology Inc (UBX) is negative, P/E ratio is not available.
The P/B ratio of Unity Biotechnology Inc (UBX) is 2.59 times as on 08-Aug-2025, a 41 discount to its peers’ median range of 4.41 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
The 52-week high and low of Unity Biotechnology Inc (UBX) are Rs 3.10 and Rs 0.07 as of 30-Apr-2026.
Unity Biotechnology Inc (UBX) has a market capitalisation of $ 3 Mln as on 08-Aug-2025. As per SEBI classification, it is a Small Cap company.
Before investing in Unity Biotechnology Inc (UBX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.